NCT01716520 - Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Umeclidinium/Vilanterol 62.5/25 mcg

Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)

DEVICE

Umeclidinium 62.5 mcg

Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)

DEVICE

Vilanterol 25 mcg

Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)

Trial Locations (21)

10117

GSK Investigational Site, Tallinn

10138

GSK Investigational Site, Tallinn

10367

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13581

GSK Investigational Site, Berlin

13619

GSK Investigational Site, Tallinn

14467

GSK Investigational Site, Potsdam

14469

GSK Investigational Site, Potsdam

20253

GSK Investigational Site, Hamburg

22927

GSK Investigational Site, Großhansdorf

23552

GSK Investigational Site, Lübeck

30173

GSK Investigational Site, Hanover

39112

GSK Investigational Site, Magdeburg

51014

GSK Investigational Site, Tartu

63110

GSK Investigational Site, Rodgau

80339

GSK Investigational Site, Munich

90402

GSK Investigational Site, Nuremberg

90502

GSK Investigational Site, Haapsalu

01307

GSK Investigational Site, Dresden

04109

GSK Investigational Site, Leipzg

04103

GSK Investigational Site, Leipzig